{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:34:28Z","timestamp":1792647268262,"version":"4.5.0"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.pharmthera.2019.107396","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T11:04:41Z","timestamp":1564139081000},"page":"107396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":155,"special_numbering":"C","title":["Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy"],"prefix":"10.1016","volume":"203","author":[{"given":"Jean-Fran\u00e7ois","family":"Goossens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2019.107396_bb0005","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/CEJ.0000000000000198","article-title":"Opposing effects of bile acids deoxycholic acid and ursodeoxycholic acid on signal transduction pathways in oesophageal cancer cells","volume":"25","author":"Abdel-Latif","year":"2016","journal-title":"European Journal of Cancer Prevention"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.steroids.2018.09.006","article-title":"Clickable conjugates of bile acids and nucleosides: Synthesis, characterization, in vitro anticancer and antituberculosis studies","volume":"139","author":"Agarwal","year":"2018","journal-title":"Steroids"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0015","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/jnci\/dji144","article-title":"Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence","volume":"97","author":"Alberts","year":"2005","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nrgastro.2017.20","article-title":"Gut microbiota modulation of chemotherapy efficacy and toxicity","volume":"14","author":"Alexander","year":"2017","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0025","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bbrc.2010.08.121","article-title":"Ursodeoxycholic acid modulates the ubiquitin-proteasome degradation pathway of p53","volume":"400","author":"Amaral","year":"2010","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0030","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1194\/jlr.R900011-JLR200","article-title":"Bile acids: Regulation of apoptosis by ursodeoxycholic acid","volume":"50","author":"Amaral","year":"2009","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0035","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/bs.irn.2017.02.008","article-title":"Antiinflammatory and hepatoprotective medicinal herbs as potential substitutes for bear bile","volume":"135","author":"Appiah","year":"2017","journal-title":"International Review in Neurobiology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0040","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<725::AID-IJC19>3.0.CO;2-4","article-title":"Intracellular Ca2+ release mediates ursolic acid-induced apoptosis in human leukemic HL-60 cells","volume":"73","author":"Baek","year":"1997","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0045","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/1940-6207.CAPR-15-0276","article-title":"Clinical study of ursodeoxycholic acid in Barrett's esophagus patients","volume":"9","author":"Banerjee","year":"2016","journal-title":"Cancer Prevention Research"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0050","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1023\/B:DDAS.0000043365.39251.6e","article-title":"Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress","volume":"49","author":"Bernardes-Silva","year":"2004","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0055","series-title":"Process for preparing high purity ursodeoxycholic acid","author":"Bonaldi","year":"1983"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5152\/tjg.2018.17521","article-title":"Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia","volume":"29","author":"Bordbar","year":"2018","journal-title":"Turkish Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0065","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1471-230X-13-155","article-title":"Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity","volume":"13","author":"Buryova","year":"2013","journal-title":"BMC Gastroenterology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0070","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S2210-7401(12)70023-2","article-title":"Chemoprevention of colorectal cancer with ursodeoxycholic acid: Cons","volume":"36","author":"Carey","year":"2012","journal-title":"Clinical Research in Hepatology and Gastroenterology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0075","doi-asserted-by":"crossref","first-page":"61021","DOI":"10.18632\/oncotarget.10477","article-title":"The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines","volume":"7","author":"Carino","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0080","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1007\/s10620-014-3190-7","article-title":"Differential regulation of EGFR-MAPK signaling by deoxycholic acid (DCA) and ursodeoxycholic acid (UDCA) in colon cancer","volume":"59","author":"Centuori","year":"2014","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0085","article-title":"Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis","author":"Chen","year":"2019","journal-title":"Clinical Review in Allergy and Immunology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0090","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/cells8030253","article-title":"Ursodeoxycholic acid regulates hepatic energy homeostasis and white adipose tissue macrophages polarization in leptin-deficiency obese mice","volume":"8","author":"Chen","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0095","first-page":"979","article-title":"Apoptotic activity of novel bile acid derivatives in human leukemic T cells through the activation of caspases","volume":"18","author":"Choi","year":"2001","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3835(03)00351-3","article-title":"Apoptosis and modulation of cell cycle control by synthetic derivatives of ursodeoxycholic acid and chenodeoxycholic acid in human prostate cancer cells","volume":"199","author":"Choi","year":"2003","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0105","first-page":"1739","article-title":"Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth","volume":"25","author":"Chung","year":"2011","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0110","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cmdc.201300059","article-title":"Synthesis and evaluation of water-soluble prodrugs of ursodeoxycholic acid (UDCA), an anti-apoptotic bile acid","volume":"8","author":"Dosa","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0115","first-page":"588","article-title":"A facile route to ursodeoxycholic acid based on stereocontrolled conversion and aggregation behavior research","volume":"48","author":"Dou","year":"2016","journal-title":"Synthesis"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0120","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"106","author":"Eaton","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0125","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00280-016-3018-6","article-title":"Sorafenib metabolism, transport, and enterohepatic recycling: Physiologically based modeling and simulation in mice","volume":"77","author":"Edginton","year":"2016","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0130","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/hep.1840040222","article-title":"Franco-Belgian cooperative study of ursodeoxycholic acid in the medical dissolution of gallstones: A double-blind, randomized, dose-response study, and comparison with chenodeoxycholic acid","volume":"4","author":"Erlinger","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13287-016-0439-4","article-title":"Bile acid: A potential inducer of colon cancer stem cells","volume":"7","author":"Farhana","year":"2016","journal-title":"Stem Cell Research & Therapy"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0140","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.bbamcr.2009.05.003","article-title":"Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR","volume":"1793","author":"Feldman","year":"2009","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1746-4269-5-2","article-title":"Bear bile: Dilemma of traditional medicinal use and animal protection","volume":"5","author":"Feng","year":"2009","journal-title":"Journal of Ethnobiology and Ethnomedicine"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0150","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1749-6632.2009.04710.x","article-title":"Apoptosis and modulation of cell cycle control by bile acids in human leukemia T cells","volume":"1171","author":"Fimognari","year":"2009","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0155","series-title":"Handbook of Experimental Pharmacology","doi-asserted-by":"crossref","DOI":"10.1007\/164_2019_238","article-title":"The pharmacology of bile acids and their receptors","author":"Fiorucci","year":"2019"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0160","series-title":"Handbook in Experimental Pharmacology","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/164_2016_110","article-title":"Mitochondrial cholesterol and the paradox in cell death","volume":"Vol. 240","author":"Garc\u00eda-Ruiz","year":"2017"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0165","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1021\/jm900872z","article-title":"Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: Potential impact in diabetes","volume":"53","author":"Genet","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0170","doi-asserted-by":"crossref","first-page":"34402","DOI":"10.18632\/oncotarget.5353","article-title":"The G-protein-coupled bile acid receptor Gpbar1 (TGR5) suppresses gastric cancer cell proliferation and migration through antagonizing STAT3 signaling pathway","volume":"6","author":"Guo","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0175","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00520-018-4367-y","article-title":"Irinotecan-induced neutropenia is reduced by oral alkalization drugs: Analysis using retrospective chart reviews and the spontaneous reporting database","volume":"27","author":"Hamano","year":"2019","journal-title":"Supportive Care in Cancer"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0180","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/biom8040159","article-title":"Overview of bile acids signaling and perspective on the signal of ursodeoxycholic acid, the most hydrophilic bile acid, in the heart","volume":"8","author":"Hanafi","year":"2018","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0185","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s10620-013-2772-0","article-title":"Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: A meta-analysis","volume":"58","author":"Hansen","year":"2013","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.steroids.2018.10.009","article-title":"A facile synthesis of ursodeoxycholic acid and obeticholic acid from cholic acid","volume":"140","author":"He","year":"2018","journal-title":"Steroids"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0195","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1152\/physrev.00054.2017","article-title":"Guts and gall: Bile acids in regulation of intestinal epithelial function in health and disease","volume":"98","author":"Hegyi","year":"2018","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0200","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.yexcr.2012.02.004","article-title":"Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells","volume":"318","author":"van Heumen","year":"2012","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0205","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1750-1172-8-118","article-title":"Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: A multicentre, randomized controlled trial","volume":"8","author":"van Heumen","year":"2013","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0210","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1194\/jlr.R049437","article-title":"Key discoveries in bile acid chemistry and biology and their clinical applications: History of the last eight decades","volume":"55","author":"Hofmann","year":"2014","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0215","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ygyno.2007.07.072","article-title":"Novel cytotoxic agents from an unexpected source: Bile acids and ovarian tumor apoptosis","volume":"107","author":"Horowitz","year":"2007","journal-title":"Gynecologic Oncology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0220","article-title":"The association of ursodeoxycholic acid use with colorectal cancer risk: A nationwide cohort study","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0225","doi-asserted-by":"crossref","first-page":"G278","DOI":"10.1152\/ajpgi.00092.2011","article-title":"Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-\u03baB activation in benign Barrett's epithelial cells","volume":"301","author":"Huo","year":"2011","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0230","doi-asserted-by":"crossref","first-page":"7110","DOI":"10.1038\/s41598-018-25569-4","article-title":"Bile acids and their respective conjugates elicit different responses in neonatal cardiomyocytes: Role of Gi protein, muscarinic receptors and TGR5","volume":"8","author":"Ibrahim","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0235","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1872-034X.2007.00297.x","article-title":"Ursodeoxycholic acid: Mechanism of action and novel clinical applications","volume":"38","author":"Ikegami","year":"2008","journal-title":"Hepatology Research"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0240","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-05-0107","article-title":"Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid","volume":"5","author":"Ikegami","year":"2006","journal-title":"Molecular Cancer Therapy"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2004.11.055","article-title":"Synthetic bile acid derivatives induce apoptosis through a c-Jun N-terminal kinase and NF-kappaB-dependent process in human cervical carcinoma cells","volume":"229","author":"Im","year":"2005","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0250","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jn\/134.2.483","article-title":"Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR\/Raf-1\/ERK signaling in human colon cancer cells","volume":"134","author":"Im","year":"2004","journal-title":"Journal of Nutrition"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0255","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0304-3835(00)00671-6","article-title":"Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells","volume":"163","author":"Im","year":"2001","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0260","first-page":"2997","article-title":"Ursodeoxycholic acid inhibits hepatocyte-like cell apoptosis by down-regulating the expressions of Bax and Caspase-3","volume":"89","author":"Ji","year":"2009","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0265","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/cancers11050647","article-title":"The role of AMP-activated protein kinase as a potential target of treatment of hepatocellular carcinoma","volume":"11","author":"Jiang","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0270","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1113\/jphysiol.2013.252544","article-title":"Ursodeoxycholic acid attenuates colonic epithelial secretory function","volume":"591","author":"Kelly","year":"2013","journal-title":"Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0275","first-page":"3517","article-title":"Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer","volume":"63","author":"Khare","year":"2003","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0280","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/01635580701883003","article-title":"Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: Roles of Ras, p38, and CCAAT\/enhancer-binding protein","volume":"60","author":"Khare","year":"2008","journal-title":"Nutrition and Cancer"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0285","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0304-3835(99)00251-7","article-title":"Inhibition of initiation of simian virus 40 DNA replication in vitro by the ursodeoxycholic acid and its derivatives","volume":"146","author":"Kim","year":"1999","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0290","article-title":"Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0295","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2174\/156800906779010236","article-title":"Modulation of the cell cycle and induction of apoptosis in human cancer cells by synthetic bile acids","volume":"6","author":"Kim","year":"2006","journal-title":"Current Cancer Drug Targets"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0300","first-page":"2585","article-title":"Ursodeoxycholic acid attenuates 5-fluorouracil-induced mucositis in a rat model","volume":"16","author":"Kim","year":"2018","journal-title":"Oncology Letters"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0305","first-page":"3632","article-title":"Ursodeoxycholic acid suppresses epithelial-mesenchymal transition and cancer stem cell formation by reducing the levels of peroxiredoxin II and reactive oxygen species in pancreatic cancer cells","volume":"38","author":"Kim","year":"2017","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0310","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.3390\/ijms13078882","article-title":"Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: Ursodeoxycholic acid freezes regeneration & induces hibernation mode","volume":"13","author":"Kotb","year":"2012","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0315","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/ijc.26336","article-title":"UDCA slows down intestinal cell proliferation by inducing high and sustained ERK phosphorylation","volume":"130","author":"Krishna-Subramanian","year":"2012","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0320","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1053\/gast.1997.v113.pm9322525","article-title":"Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas","volume":"113","author":"Kullak-Ublick","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0325","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.3390\/ijms19103234","article-title":"Sorafenib in combination with betulinic acid synergistically induces cell cycle arrest and inhibits clonogenic activity in pancreatic ductal adenocarcinoma cells","volume":"19","author":"Kutkowska","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0330","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bcp.2016.08.011","article-title":"Identification of a novel oxidative stress induced cell death by sorafenib and oleanolic acid in human hepatocellular carcinoma cells","volume":"118","author":"Lange","year":"2016","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0335","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","article-title":"Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders","volume":"35","author":"Lazaridis","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2017.05.011","article-title":"Ursodeoxycholic acid attenuates experimental autoimmune arthritis by targeting Th17 and inducing pAMPK and transcriptional corepressor SMILE","volume":"188","author":"Lee","year":"2017","journal-title":"Immunology Letters"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0345","doi-asserted-by":"crossref","first-page":"981","DOI":"10.5414\/CP201849","article-title":"Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1\u03b1, did not increase the systemic exposure of pitavastatin","volume":"52","author":"Lee","year":"2014","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0350","first-page":"2551","article-title":"Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK","volume":"42","author":"Lee","year":"2018","journal-title":"International Journal of Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0355","doi-asserted-by":"crossref","first-page":"16","DOI":"10.15430\/JCP.2017.22.1.16","article-title":"Ursodeoxycholic acid induces death receptor-mediated apoptosis in prostate cancer cells","volume":"22","author":"Lee","year":"2017","journal-title":"Journal of Cancer Prevention"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0360","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0140-6736(87)91812-5","article-title":"Treatment of primary biliary cirrhosis and cholestatic disorders with ursodeoxycholic acid","volume":"2","author":"Leuschner","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0365","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/CAD.0000000000000750","article-title":"Cotreatment with sorafenib and oleanolic acid induces reactive oxygen species-dependent and mitochondrial-mediated apoptotic cell death in hepatocellular carcinoma cells","volume":"30","author":"Liese","year":"2019","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0370","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/ijc.24853","article-title":"Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma","volume":"126","author":"Lim","year":"2010","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0375","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/carcin\/bgr038","article-title":"Lipid raft-dependent death receptor 5 (DR5) expression and activation are critical for ursodeoxycholic acid-induced apoptosis in gastric cancer cells","volume":"32","author":"Lim","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0380","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3892\/or.2012.1918","article-title":"Pro-apoptotic role of the MEK\/ERK pathway in ursodeoxycholic acid-induced apoptosis in SNU601 gastric cancer cells","volume":"28","author":"Lim","year":"2012","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0385","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3892\/or.2015.4076","article-title":"Ursodeoxycholic acid effectively kills drug-resistant gastric cancer cells through induction of autophagic death","volume":"34","author":"Lim","year":"2015","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0390","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.canlet.2008.05.014","article-title":"Synthetic chenodeoxycholic acid derivative, HS-1200, induces apoptosis of human hepatoma cells via a mitochondrial pathway","volume":"270","author":"Liu","year":"2008","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0395","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3748\/wjg.v13.i11.1652","article-title":"Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines","volume":"13","author":"Liu","year":"2007","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0400","doi-asserted-by":"crossref","first-page":"10367","DOI":"10.3748\/wjg.v21.i36.10367","article-title":"Ursodeoxycholic acid induces apoptosis in hepatocellular carcinoma xenografts in mice","volume":"21","author":"Liu","year":"2015","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0405","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.canlet.2017.10.017","article-title":"The membrane bile acid receptor TGR5 drives cell growth and migration via activation of the JAK2\/STAT3 signaling pathway in non-small cell lung cancer","volume":"412","author":"Liu","year":"2018","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0410","first-page":"690","article-title":"Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid","volume":"72","author":"Makino","year":"1975","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0415","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/cmdc.201800756","article-title":"Dihydroartemisinin-bile acid hybridization as an effective approach to enhance dihydroartemisinin anticancer activity","volume":"14","author":"Marchesi","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0420","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1292\/jvms.10-0034","article-title":"Hepatocellular carcinoma in a Hokkaido brown bear (Ursus arctos yesoensis)","volume":"72","author":"Matsuda","year":"2010","journal-title":"The Journal of Veterinary Medical Science"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0425","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/08880018.2012.713083","article-title":"Hepatoprotective efficacy of ursodeoxycholic acid in pediatrics acute lymphoblastic leukemia","volume":"29","author":"Mohammed Saif","year":"2012","journal-title":"Pediatric Hematology and Oncology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0430","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4143\/crt.2004.36.2.132","article-title":"Synthetic CDCA derivatives-induced apoptosis of stomach cancer cell line SNU-1 cells","volume":"36","author":"Moon","year":"2004","journal-title":"Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0435","doi-asserted-by":"crossref","first-page":"G378","DOI":"10.1152\/ajpgi.00435.2016","article-title":"The bile acids, deoxycholic acid and ursodeoxycholic acid, regulate colonic epithelial wound healing","volume":"314","author":"Mroz","year":"2018","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0440","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1021\/acsmedchemlett.6b00257","article-title":"NO photoreleaser-deoxyadenosine and -bile acid derivative bioconjugates as novel potential photochemotherapeutics","volume":"7","author":"Navacchia","year":"2016","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0445","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3390\/molecules22101710","article-title":"Rational design of nucleoside-bile acid conjugates incorporating a triazole moiety for anticancer evaluation and SAR exploration","volume":"22","author":"Navacchia","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0450","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/cancers10100367","article-title":"Molecular scoring of hepatocellular carcinoma for predicting metastatic recurrence and requirements of systemic chemotherapy","volume":"10","author":"Nishida","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0455","first-page":"145","article-title":"A practical review of primary biliary cholangitis for the gastroenterologist","volume":"15","author":"Onofrio","year":"2019","journal-title":"Gastroenterology and Hepatology (NY)"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0460","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.3390\/nu7053200","article-title":"Anticancer effect of ursodeoxycholic acid in human oral squamous carcinoma HSC-3 cells through the caspases","volume":"7","author":"Pang","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0465","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.3892\/ol.2016.4842","article-title":"Tauroursodeoxycholic acid reduces the invasion of MDA-MB-231 cells by modulating matrix metalloproteinases 7 and 13","volume":"12","author":"Park","year":"2016","journal-title":"Oncology Letters"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0470","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.bbrc.2008.06.014","article-title":"Ursodeoxycholic acid prevents apoptosis of mouse sensory neurons induced by cisplatin by reducing P53 accumulation","volume":"377","author":"Park","year":"2008","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0475","first-page":"231","article-title":"Synthetic bile acid derivatives inhibit cell proliferation and induce apoptosis in HT-29 human colon cancer cells","volume":"25","author":"Park","year":"2004","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0480","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.canlet.2008.04.038","article-title":"A chenodeoxycholic derivative, HS-1200, induces apoptosis and cell cycle modulation via Egr-1 gene expression control on human hepatoma cells","volume":"270","author":"Park","year":"2008","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0485","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF02974038","article-title":"Induction of apoptosis in HepG2 human hepatocellular carcinoma cells by a novel derivative of ursodeoxycholic acid (UDCA)","volume":"20","author":"Park","year":"1997","journal-title":"Archives of Pharmaceutical Research"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0490","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/cam4.1965","article-title":"Effects of ursodeoxycholic acid on the gut microbiome and colorectal adenoma development","volume":"8","author":"Pearson","year":"2019","journal-title":"Cancer Medicine"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0495","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CEJ.0b013e32834ef16f","article-title":"The chemopreventive agent ursodeoxycholic acid inhibits proliferation of colon carcinoma cells by suppressing c-Myc expression","volume":"21","author":"Peir\u00f3-Jord\u00e1n","year":"2012","journal-title":"European Journal of Cancer Prevention"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0500","doi-asserted-by":"crossref","first-page":"G129","DOI":"10.1152\/ajpgi.00085.2014","article-title":"In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids","volume":"307","author":"Peng","year":"2014","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0505","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ijc.2910610107","article-title":"Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids","volume":"61","author":"Pongracz","year":"1995","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0510","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","article-title":"Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?","volume":"1","author":"Poupon","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0515","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC study group","volume":"330","author":"Poupon","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0520","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1471-2407-6-219","article-title":"Resistance to ursodeoxycholic acid-induced growth arrest can also result in resistance to deoxycholic acid-induced apoptosis and increased tumorgenicity","volume":"6","author":"Powell","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0525","first-page":"70","article-title":"Stability of compounded Ursodiol suspensions in PCCA base, SuspendIt","volume":"23","author":"Pramar","year":"2019","journal-title":"International Journal of Pharmaceutical Compounding"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0530","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/19490976.2015.1127483","article-title":"Consequences of bile salt biotransformations by intestinal bacteria","volume":"7","author":"Ridlon","year":"2016","journal-title":"Gut Microbes"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0535","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/molecules23030679","article-title":"Novel semisynthetic derivatives of bile acids as effective tyrosyl-DNA phosphodiesterase 1 inhibitors","volume":"23","author":"Salomatina","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0540","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.28932","article-title":"Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis","volume":"65","author":"Samur","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0545","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.phrs.2018.08.008","article-title":"Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials","volume":"135","author":"S\u00e1nchez-Garc\u00eda","year":"2018","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0550","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fphar.2018.00939","article-title":"Bile acid synthesis: From nature to the chemical modification and synthesis and their applications as drugs and nutrients","volume":"9","author":"\u0160arenac","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0555","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1021\/jm7015864","article-title":"Novel potent and selective bile acid derivatives as TGR5 agonists: Biological screening, structure-activity relationships, and molecular modeling studies","volume":"51","author":"Sato","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0560","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112731","article-title":"Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity","volume":"9","author":"Seidensticker","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0565","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00001813-200303000-00005","article-title":"Synthetic chenodeoxycholic acid derivative HS-1200-induced apoptosis of p815 mastocytoma cells is augmented by co-treatment with lactacystin","volume":"14","author":"Seo","year":"2003","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0570","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S2210-7401(12)70022-0","article-title":"Chemoprevention of colorectal cancer with ursodeoxycholic acid: Pro","volume":"36","author":"Serfaty","year":"2012","journal-title":"Clinical Research in Hepatology and Gastroenterology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0575","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/jhep.2003.50311","article-title":"Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: An observational study","volume":"38","author":"Serfaty","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0580","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.ejca.2005.06.015","article-title":"Ursodeoxycholic acid inhibits translocation of protein kinase C in human colonic cancer cell lines","volume":"41","author":"Shah","year":"2005","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0585","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ijc.21365","article-title":"Ursodeoxycholic acid inhibits interleukin 1 beta [corrected] and deoxycholic acid-induced activation of NF-kappaB and AP-1 in human colon cancer cells","volume":"118","author":"Shah","year":"2006","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0590","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/jm100860s","article-title":"Ursodeoxycholic acid amides as novel glucocorticoid receptor modulators","volume":"54","author":"Sharma","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0595","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1634\/theoncologist.2013-0436","article-title":"Learning from gus","volume":"19","author":"Shuman","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0600","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1039\/C4MD00223G","article-title":"Synthesis, structure-activity relationship, and mechanistic investigation of lithocholic acid amphiphiles for colon cancer therapy","volume":"6","author":"Singh","year":"2015","journal-title":"MedChemComm"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0605","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/MIB.0b013e318286fa61","article-title":"Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: A systematic review and meta-analysis","volume":"19","author":"Singh","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0610","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1021\/bc300664k","article-title":"Design, synthesis, and mechanistic investigations of bile acid-tamoxifen conjugates for breast cancer therapy","volume":"24","author":"Sreekanth","year":"2013","journal-title":"Bioconjugate Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0615","doi-asserted-by":"crossref","first-page":"54378","DOI":"10.18632\/oncotarget.17533","article-title":"The G-protein-coupled bile acid receptor Gpbar1 (TGR5) protects against renal inflammation and renal cancer cell proliferation and migration through antagonizing NF-\u03baB and STAT3 signaling pathways","volume":"8","author":"Su","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0620","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0304-3835(97)04604-1","article-title":"Anti-angiogenic activity of ursodeoxycholic acid and its derivatives","volume":"113","author":"Suh","year":"1997","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0625","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0630","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1158\/1940-6207.CAPR-09-0234","article-title":"Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients","volume":"2","author":"Thompson","year":"2009","journal-title":"Cancer Prevention Research (Phila)"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0635","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3762\/bjoc.14.33","article-title":"Latest development in the synthesis of ursodeoxycholic acid (UDCA): A critical review","volume":"14","author":"Tonin","year":"2018","journal-title":"Beilstein Journal of Organic Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2010.04.023","article-title":"A concentration-dependent effect of ursodeoxycholate on apoptosis and caspases activities of HepG2 hepatocellular carcinoma cells","volume":"640","author":"Tsagarakis","year":"2010","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0645","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7326\/0003-4819-134-2-200101160-00008","article-title":"Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"134","author":"Tung","year":"2001","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0650","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10620-007-9949-3","article-title":"Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity","volume":"53","author":"Uraz","year":"2008","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0655","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7453\/gahmj.2014.017","article-title":"The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases","volume":"3","author":"Vang","year":"2014","journal-title":"Global Advances in Health and Medicine"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0660","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/01635581.2017.1263747","article-title":"Effects of supernatants from Escherichia coli Nissle 1917 and Faecalibacterium prausnitzii on intestinal epithelial cells and a rat model of 5-fluorouracil-induced mucositis","volume":"69","author":"Wang","year":"2017","journal-title":"Nutrition and Cancer"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0665","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jcmm.13964","article-title":"Betulinic acid induces apoptosis and suppresses metastasis in hepatocellular carcinoma cell lines in vitro and in vivo","volume":"23","author":"Wang","year":"2019","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0670","doi-asserted-by":"crossref","first-page":"G550","DOI":"10.1152\/ajpgi.00256.2016","article-title":"Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon","volume":"312","author":"Ward","year":"2017","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0675","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s41374-018-0062-3","article-title":"The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma","volume":"8","author":"Wu","year":"2018","journal-title":"Laboratory Investigation"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0680","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12935-018-0569-0","article-title":"The role of bile acids in cellular invasiveness of gastric cancer","volume":"18","author":"Wu","year":"2018","journal-title":"Cancer Cell International"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0685","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/molecules24061179","article-title":"Enhanced liver targeting of camptothecin via conjugation with deoxycholic acid","volume":"24","author":"Xiao","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0690","first-page":"1465912","article-title":"Chenodeoxycholic acid derivative HS-1200 inhibits hepatocarcinogenesis and improves liver function in diethylnitrosamine-exposed rats by downregulating MTH1","volume":"2017","author":"Xu","year":"2017","journal-title":"Biomedical Research International"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0695","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113479","article-title":"U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR\/S6K1 and cyclin\/CDK complex pathways","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0700","first-page":"919","article-title":"A novel chenodeoxycholic derivative HS-1200 enhances radiation-induced apoptosis in MCF-7 cells","volume":"17","author":"Yee","year":"2007","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0705","first-page":"653","article-title":"Synthetic chenodeoxycholic acid derivatives inhibit glioblastoma multiform tumor growth in vitro and in vivo","volume":"27","author":"Yee","year":"2005","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0710","first-page":"213","article-title":"Apoptosis induced by ursodeoxycholic acid in human melanoma cells through the mitochondrial pathway","volume":"41","author":"Yu","year":"2019","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0715","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/jb\/mvi106","article-title":"Characteristics of apoptosis in HCT116 colon cancer cells induced by deoxycholic acid","volume":"138","author":"Yui","year":"2005","journal-title":"Journal of Biochemistry"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0720","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijpharm.2016.06.139","article-title":"Transporter-targeted cholic acid-cytarabine conjugates for improved oral absorption","volume":"511","author":"Zhang","year":"2016","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0725","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13046-018-0985-y","article-title":"Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer","volume":"38","author":"Zhang","year":"2019","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0730","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1111\/bph.14705","article-title":"Ursodeoxycholic acid accelerates bile acid enterohepatic circulation","volume":"176","author":"Zhang","year":"2019","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0735","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/cbic.201700415","article-title":"Continuous production of Ursodeoxycholic acid by using two Cascade reactors with co-immobilized enzymes","volume":"19","author":"Zheng","year":"2018","journal-title":"ChemBioChem"},{"key":"10.1016\/j.pharmthera.2019.107396_bb0740","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/1751-2980.12191","article-title":"Ursodeoxycholic acid induces apoptosis of hepatocellular carcinoma cells in vitro","volume":"15","author":"Zhu","year":"2014","journal-title":"Journal of Digestive Diseases"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725819301391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:01:36Z","timestamp":1759010496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725819301391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":148,"alternative-id":["S0163725819301391"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107396","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107396"}}